The pharma company gave several presentations at AAIC 2026 on trontinemab’s potential role in Alzheimer’s as the drug ...

Even as Roche executives on Thursday espoused confidence in the company’s resilience and growth potential over the next several years, a mix of exchange rate fluctuations and lackluster pharmaceutical ...

Roche’s leadership shuffle, which began in July, continued on Monday with the departure of pharma sector CEO Bill Anderson. Anderson, formerly the boss of Roche subsidiary Genentech, took over as ...

The 170-acre northeast-side Indianapolis campus is composed of 21 buildings and serves as one of the company’s two global hubs.

At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:RHHBY) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, ...

These two programme terminations leave Roche with just one Huntington’s disease candidate.

Swiss pharmaceutical company Roche on Wednesday reported a modest uptick in first-quarter sales. Sales were up 2% at constant exchange rates, led by stronger demand for Roche's newer medicines and ...

Pharma giant Roche is set to acquire oncology EHR software firm Flatiron Health in the first half of 2018, the companies announced today in a statement. Roche will pay an additional $1.9 billion over ...

Shares of 89bio surged Thursday after Roche announced it was buying the small-cap biopharmaceutical company for $3.5 billion. As part of the deal, 89bio shareholders will receive up to $20.50 a share ...

ZURICH, Dec 12 (Reuters) - Roche (ROG.S), opens new tab said on Monday the head of its pharmaceuticals division had decided to leave after 16 years with the Swiss drugmaker, heralding a wider ...

However, over the past year, its shares have fallen 27%. There are two likely reasons for the decline of Roche's shares. One, despite an up year for revenue in 2022, it is likely that its diagnostics ...